Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Hero

Showing results (131-140 of 141) with videos related to

Pageof 15
Sort By:
Journal of the National Cancer Institute|March 8, 2018
Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma PatientsPauline Depuydt, Valentina Boeva, Toby D Hocking, et al.
European Radiology Experimental|April 5, 2020
PRIMAGE project: predictive in silico multiscale analytics to support childhood cancer personalised evaluation empowered by imaging biomarkersLuis Martí-Bonmatí, Ángel Alberich-Bayarri, Ruth Ladenstein, et al.
Journal of the National Cancer Institute|August 25, 2025
International neuroblastoma risk group consortium: a model of a networking for rare cancersSusan L Cohn, Wendy B London, Gudrun Schleiermacher, et al.
JAMA Oncology|August 12, 2021
Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment: An International Society of Paediatric Oncology Supportive Care Consensus ReportAnnelot J M Meijer, Marry M van den Heuvel-Eibrink, Beth Brooks, et al.
Oncotarget|August 31, 2016
MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastomaJohannes Fabian, Desirée Opitz, Kristina Althoff, et al.
Science (New York, N.Y.)|December 8, 2018
A mechanistic classification of clinical phenotypes in neuroblastomaSandra Ackermann, Maria Cartolano, Barbara Hero, et al.
The Journal of Clinical Investigation|February 12, 2026
Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastomaLisa Werr, Jana Boland, Josephine Petersen, et al.
Nature|October 16, 2015
Telomerase activation by genomic rearrangements in high-risk neuroblastomaMartin Peifer, Falk Hertwig, Frederik Roels, et al.
JCO Precision Oncology|July 1, 2026
Frequency and Prognostic Significance of Genetic Abnormalities in a Subgroup of Patients With Intermediate-Risk Neuroblastoma: A SIOPEN StudyHannah E Hartley, Fang Chyi Fong, Alem S Gabriel, et al.
American Journal of Medical Genetics. Part A|February 8, 2017
Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and HematologyTim Ripperger, Stefan S Bielack, Arndt Borkhardt, et al.
Pageof 15

Showing results (131-140 of 141) with videos related to

Sort By:
Pageof 15
Journal of the National Cancer Institute|March 8, 2018
Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma PatientsPauline Depuydt, Valentina Boeva, Toby D Hocking, et al.
European Radiology Experimental|April 5, 2020
PRIMAGE project: predictive in silico multiscale analytics to support childhood cancer personalised evaluation empowered by imaging biomarkersLuis Martí-Bonmatí, Ángel Alberich-Bayarri, Ruth Ladenstein, et al.
Journal of the National Cancer Institute|August 25, 2025
International neuroblastoma risk group consortium: a model of a networking for rare cancersSusan L Cohn, Wendy B London, Gudrun Schleiermacher, et al.
JAMA Oncology|August 12, 2021
Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment: An International Society of Paediatric Oncology Supportive Care Consensus ReportAnnelot J M Meijer, Marry M van den Heuvel-Eibrink, Beth Brooks, et al.
Oncotarget|August 31, 2016
MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastomaJohannes Fabian, Desirée Opitz, Kristina Althoff, et al.
Science (New York, N.Y.)|December 8, 2018
A mechanistic classification of clinical phenotypes in neuroblastomaSandra Ackermann, Maria Cartolano, Barbara Hero, et al.
The Journal of Clinical Investigation|February 12, 2026
Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastomaLisa Werr, Jana Boland, Josephine Petersen, et al.
Nature|October 16, 2015
Telomerase activation by genomic rearrangements in high-risk neuroblastomaMartin Peifer, Falk Hertwig, Frederik Roels, et al.
JCO Precision Oncology|July 1, 2026
Frequency and Prognostic Significance of Genetic Abnormalities in a Subgroup of Patients With Intermediate-Risk Neuroblastoma: A SIOPEN StudyHannah E Hartley, Fang Chyi Fong, Alem S Gabriel, et al.
American Journal of Medical Genetics. Part A|February 8, 2017
Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and HematologyTim Ripperger, Stefan S Bielack, Arndt Borkhardt, et al.
Pageof 15